MENINGITIS MANAGEMENT COSTS IN MEXICO PART I:
Expert panel on the utilization of resources for a case of meningococcal
meningitis
PART II:Information obtained from researched
documentation
COST OF HANDLING MENINGITIS IN MEXICO PART I:
Results from a Delphi Panel: Utilization of resources for a case of meningococcal meningitis
3
BACKGROUND
MENINGOCOCCAL INVASIVE DISEASE
Meningitis and bacterial sepsis are the inflammatory response of the leptomeninges cells and the subarachnoid space against aggressions of diverse nature such as: infectious, chemical (contrast, medication), tumorous (carcinomatose meningitis) or autoimmune (vasculitis).
Worldwide incidences and prevalence are unknown; however, we do know that 70 percent of cases occur in children under 5 years of age. 75-80 percent of meningitis occurring out of the neonatal period is produced by three pathogens: meningococcus, pneumococcus and Haemophilus influenzae. For this reason they are considered critical diseases that endanger the child’s life, or can leave irreversible sequelae.
BACKGROUND
MENINGOCOCCAL INVASIVE DISEASE
Meningitis and bacterial sepsis etiology in our environment have experienced important epidemiological changes in the last years. The incidence of etiological agents is basically influenced by external factors of sanitary policy.
Bacterial origin meningitis, caused mainly by Neisseriae meningitis and Streptococcus pneumoniae, represent the most lethal form of the disease, and its distribution, morbidity and mortality are determined by the social and economic conditions of the poorest communities and countries in the World, where preventive vaccination and medication for its control are very limited by the levels of economic development.
4
5
OBJECTIVE
To identify a (cost) resource utilization pattern for a case of bacterial menigococcal meningitis within the Mexican health sector.
METHODS AND MATERIALS
DELPHI PANEL
The study was carried out by adapting Delphi methodology, in order to identify participant's response patterns through a series of sequenced questionnaires.
Some characteristics of this methodology (Delphi) include a very high minimization of influence between participants, equal opportunities for participation and a good performance with heterogeneous groups.
Verbal communication skills are not required, and even though they don’t guarantee representation of participants, written communication skills are necessary.
6
7
METHODS AND MATERIALS
DELPHI PANEL (continued)
During the first stage, a questionnaire is used as a starting point for specialists to express their individual estimations. Then, the questionnaires are collected and the responses are statistically analyzed and integrated into a second questionnaire. Specialists know and evaluate these previously obtained responses to indicate agreement or disagreement with them and corroborate or rectify the primary responses.
Just as other methods of consensus, the Delphi is proposed for problems that need to be investigated quickly and inexpensively. Its alteration depends on the area of interest and context where it's being applied, which is why variations in practice are justified.
8
METHODS AND MATERIALS
DELPHI PANEL (continued)
This analysis made use of the Delphi method in order to identify a resource utilization pattern for treatment of bacterial meningitis by meningococcus. The end result was to conduct a study of cost associated with this malady.
The study was conducted between august and october 2009
through the use of 2 questionnaires and two rounds of consultations.
METHODS AND MATERIALS
The following flow chart details the process that was followed.
9
Source: Polytechnic University of Madrid http://www.gtic.ssr.upm.es/encuestas/delphi.htm
METHODS AND MATERIALS
PARTICIPANTS
Five infectology and pediatric infectology specialists belonging to highly specialized hospitals from the public and private sector. Participant selection was carefully controlled with criteria ranging from gender, age, research activities, position in their respective hospitals and experience in treating the disease.
EXCLUSION CRITERIA
Non-infectology specialists, infectology specialists with an administrative position at the time that the evaluation was conducted.
10
METHODS AND MATERIALS
INSTRUMENTS
A questionnaire was designed and delivered to the participants via electronic format. It mainly dealt with resource utilization for the treatment of meningococcal meningitis.
Central tendency measures were obtained from the first stage of responses. The second, or validation, stage, was developed the following month. In this stage, participants were required to ratify or modify their original response.
The questionnaire, made up of fifty-two items, evaluated two sections: Acute Phase and Management of Sequelae.
11
12
METHODS AND MATERIALS
ACUTE PHASE
First contact and follow-up
Hospitalization
Number of cases attended to in clinical practice
Laboratory studies
Cabinet studies
Invasive medical procedures
Pharmacological treatment
Blood transfusion and hemoderivatives
Relatives that were recommended for prophylaxis and medicine
13
METHODS AND MATERIALS
SEQUELAE MANAGEMENT
Types of sequelae and patient percentage
Appointment follow-up (twelve month period by types of sequelae)
Laboratory studies (twelve month period by types of sequelae)
Cabinet studies (twelve month period by types of sequelae)
Medical devices by sequelae
Pharmacological treatment (twelve month period by types of sequelae)
Patient survival (percentage)
Diminhed quality of life (percentage)
Amputation costs
14
ANALYSES AND RESULTS
DATA
The study was conducted in order to find out resource utilization when treating a typical or average case of a patient with bacterial meningitis by meningococcal.
The following results were obtained by a second questionnaire (validation); they were statistically processed and provided central tendency measures.
Results analysis and diagram presentation used the median, as it is less sensitive to variable oscillation values than the mean, therefore not affected by dispersion.
15
ANALYSES AND RESULTS
MAIN FINDINGS
Average meningitis meningococcus cases that specialists have worked with: 7
Average of hospital stay, caused by meningococcal meningitis: 16 Percentage of patients that retain sequelae after disease was
presented: 50%. Survival percentage: 70%. Epilepsy, amputations, and mild hypoacusia are the most prevalent
sequelae, after the disease presents itself. Given the sequelae, rehabilitation appointments are a top priority for
patients that presented meningococcemia profiles. Cost of minor amputation: 20 thousand pesos; Cost of major
amputation: 50 thousand pesos. No information on medication use was found, even when this category
was explicitly researched.
ANALYSES AND RESULTS
16
MAIN RESULTS
Type and number of consultations that intervened in a case of meningococcemia
Acute Phase1st Contact and Monitoring
Number of Specialty Consultations
1 1 1 13 4 4.5
22
Neurology
Pediatrics or in
ternal medicine
Intensive care
Emergency
Neurosurgery
Consultation with Specialist (total)
Infectology
Rehabilitation
MAIN RESULTS
Average of hospital stay, caused by a case of meningococcal meningitis
17
Acute PhaseAverage Hospital Stay
1
7
8
Emergency ICU Hospital f loor
ANALYSES AND RESULTS
ANALYSES AND RESULTS
18
MAIN
RESULTS
Laboratory Studies that intervene with treating a case of
meningitis by meningococcus.
Acute PhaseLaboratory Test
0.5 0.51
1.5 1.52 2
2.5 2.5 2.5 2.75 3 3 3 3 33.5 3.53.75
7
8
11
6.5
54.54.5
44444
ANALYSES AND RESULTS
MAIN RESULTS
Cabinet Studies used for treating a case of meningococcal meningitis
19
Acute PhaseCabinet Studies
1 1 11.5
2 2 22.5
9
Ultr
ason
ogra
phy
MR
IEc
hoca
rdio
gram
s
CT
scan
EEG
BAER VE
PEl
ectro
card
iogr
ams
X-R
ays
ANALYSES AND RESULTS
MAIN RESULTS
Invasive medical procedures used for treating a case of meningococcal meningitis
20
Acute PhaseInvasive Medical Procedures
2.5
4.55
10.25
Lumbar punctures Endotracheal intubation(no. of days)
Arterioclisis (no. of days) Central catheters (no. ofdays)
ANALYSES AND RESULTS
MAIN RESULTS
Blood transfusions and hemoderivatives for treatment of meningitis meningococcal
21
Acute PhaseBlood transfusions and hemoderivatives
22.25
4.5
6
Gamma globulins Globular packages FFP Platelet count
ANALYSES AND RESULTS
MAIN RESULTS
Percentage of sequelae by meningitis meningococcal
22
Sequelae ManagementSequelae (% of patients)
2% 4% 8%
8%
8%
8%
9%9%14%
30%
Loss of visual acuity
Sore / Grafts
Severe hearing loss
Mental retardation
Sensory-motor deficit
Hydrocephalus
Mediated hearing loss
Amputations
Epilepsy
No sequelae
ANALYSES AND RESULTS
MAIN RESULTS
Amputation costs
23
Sequelae ManagementAmputation Costs
$20,000
$50,000
Minor amputation
Major amputation
ANALYSES AND RESULTS
24
Cost per expert physician survey. 1st Round (Only medical attention costs are included)Cost Source: DOF 16 April 2007 updated for 2009
Item/ Physician Specialist
1 Specialist
2 Specialist
3 Specialist
4 Specialist
5 General medicine 1 Emergency room 2nd level 1 3rd level 1 Specialty 2nd level 32 3rd level 4 4 25 Hospitalization Days Hospitalized 2nd level 9 3rd level 11 8 5 11 Days in ICU 5 7 5 8 10 Clinical Analyses Applied 76 64 8 86 224 Radiodiagnostic 10 4 8 10 CAT 1 1 3 5 NMR 1 2 2 Electrodiagnostic 4 2 5 12 Ultrasonography 2 1 13 Costs Consultation Costs $2,184 $5,260 $5,260 $1,105 $32,875 Hospitalization Cost $192,844 $234,691 $164,230 $267,537 $333,229 Cost for applied analyses $20,902 $26,168 $736 $56,467 $93,408 Total $215,930 $266,119 $170,226 $325,109 $459,512
ANALYSES AND RESULTS
25
Cost per expert physician survey. Concensus (only medical attention costs are included)Cost Source DOF 16 April 2007 updated to 2009
Item Consensus General medicine Emergency room 2nd level 1 3rd level Specialty 2nd level 3rd level 15 Hospitalization Days Hospitalized 2nd level 3rd level 8 Days in ICU 7 Clinical Analyses Applied 112 Radiodiagnostic 9 CAT 2 NMR 1 Electrodiagnostic 7 Ultrasonography 1 Costs Consultation Costs $20,830 Hospitalization Cost $234,691 Cost for applied analyses $42,149 Total $297,670
MENINGITIS TREATMENT COSTS IN MEXICOPART II:
Hospital Files Evaluated
ANALYSES AND RESULTS: Cost of Meningococcal Meningitis
27
27Cost of medical files:2 patients detected with meningitis meningococcus: 1 at the “Hospital de Infectología CMN La Raza del IMSS” and 1 in the Private Sector (For this one, cost estimations were made through a public sector tabulator) Cost source: DOF 16 April 2007 updated to 2009
Patient with Meningococcal Meningitis
Item Public Sector
Private Sector
General medicine Emergency room 2nd level 3 3rd level 1 Specialty 2nd level 3rd level 42 3 Hospitalization Days Hospitalized 2nd level 3rd level 6 Days in ICU 10 1 Clinical Analyses Applied 4 35 Radiodiagnostic 1 3 CAT NMR Electrodiagnostic 2 Ultrasonography Costs Consultation Costs $58,545.00 $5,612 Hospitalization Cost $309,384.00 $28,077 Cost for applied analyses $738.00 $4,820 Cost for pharmacological treatment $496.31
Total $369,163.31 $38,509
ANALYSES AND RESULTS: Cost of Bacterial Meningitis (not meningococcus)
28
28
Cost of medical records. (6 patients detected in the “Hospital de Infectología- CMN La Raza del IMSS” )-Cost source:DOF 16 April 2007 updated to 2009
Item/ Patient Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
General medicine 1 2 Emergency room 2nd level 1 1 1 3rd level 1 2 1 Specialty 2nd level 1 3rd level 3 2 4 7 Hospitalization Days Hospitalized 2nd level 13 3rd level 17 10 45 1 Days in ICU 8 7 9 9 8 30 Clinical Analyses Applied 16 125 98 24 18 11 Radiodiagnostic 2 1 2 2 CAT 1 1 5 1 NMR 1 0 Electrodiagnostic 1 1 2 Ultrasonography 1 1 Costs Consultation Costs $6,129.00 $0.00 $5,964.00 $1,105.00 $7,399.00 $11,977.00 Hospitalization Cost $305,689.00 $306,226.00 $252,693.00 $252,693.00 $439,221.00 $847,079.00 Cost for applied analyses $10,702.00 $29,810.00 $9,261.00 $3,318.00 $44,351.00 $11,102.00 Cost for pharmacological treatment $5,087.61 $1,550.90 $4,310.54 $33,491.19 $40,716.33 $3,544.74 Total $327,607.61 $337,586.90 $272,228.54 $290,607.19 $531,687.33 $873,702.74
2929
30
Gráficas que se tienen que editar (Por número de diapositiva) Diapositiva 9:
Delphi Process Task Force, Technical Team, Expert Panel
Event definition, Expert panel selections Creation of first questionnaire, First questionnaires sent
out 1st Circulation (Dentro de la flecha) 1st questionnaire responses
Statistical analysis of group responses, Addition of statistical analysis to second questionnaire, sent out
2nd circulation (Dentro de la 2da flecha) Review group responses and compare to answers from
the first questionnaires, Answer 2nd questionnaire. Final statistical analysis of group responses, Results
are presented to the task force Conclusion
30
31
Diapositiva 16: Acute Phase 1st Contact and Follow-up
Number of Specialist Consultations Neurology Pediatrics or internal medicine Intensivist Emergency Room Neurosurgery Specialist Consultations (total) Infectology Rehabilitation
Diapositiva 17: Number of Hospitalization Days: Acute Phase
Emergency Room Intensive Care Unit Main Floor
31
32
Diapositiva 18 Number of Lab Studies: Acute Phase
HIV ELISA Western Blot Immunoglobulin Catheter Tip Uroculture Coproculture LCR Cultures Hepatic Function Panel Anticonvulsants Hemocultures Secretions Reactive Protein C Dimero D Fibrinogeno
32
33
Cultures (total) Renal Function EGO PCR Blood Chemistry Electrolytes Vein Geometry VSG Arterial Geometry
Diapositiva 19: Acute Phase Procedures: Cabinet Studies
Ultrasonography RMIN Ecocardiogram CAT Electroencephalogram Auditory Potentials
33
34
Electrocardiograms X-Rays
Diapositiva 20: Acute Phase: Invasive Medicine Procedures
Lumbar Puncture Arteriaclasis (number of days)
Diapositiva 21: Acute Phase: Blood and Hemoderivative
Transfusion Gamma Globulin Globular Package Fresh Concentrated Plasma Concentrated Platelets
Diapositiva 22: MM Sequelae Management (Patient Percentage)
Loss of visual acuteness Pressure Ulcer/Graft
34
35
Severe Hypoacusia Mental Retardation Motor or Sensory Deficit Hydrocephalus Mild Hypoacusia Amputations Epilepsy No Sequelae
Diapositiva 23: MM Sequelae Management: Amputation Costs
Minor Amputation Major Amputation
Diapositiva 24: Specialist (1, 2, 3, 4, 5) Item/Physician General Medicine
35